Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Importance of combined assessment of skeletal muscle mass and density by computed tomography in predicting clinical outcomes after transcatheter aortic valve replacement

Abstract

Skeletal muscle mass (SMM) as calculated by computed tomography (CT) is a predictor of all-cause mortality after transcatheter aortic valve replacement (TAVR), but it remains unclear whether using CT-determined density of skeletal muscle has additive prognostic value. We utilized the Japanese multicenter registry data of 1375 patients who underwent CT prior to TAVR. Sarcopenia status was defined by the CT-derived SMM index (threshold: men, 55.4 cm2/m2; women, 38.9 cm2/m2). The threshold for high and low CT density was based on the median value of the entire cohort (men: 33.4 HU; women: 29.5 HU). Sarcopenia was observed in 802 patients (58.3%) overall. Patients were categorized into non-sarcopenia and high-CT density (n = 298), non-sarcopenia and low-CT density (n = 275), sarcopenia and high-CT density (n = 399), and sarcopenia and low-CT density (n = 403) groups, and procedural outcomes and mortality compared. The cumulative 3-year mortality rates in these groups were 18%, 27%, 24%, and 32%, respectively. Cox-regression multivariate analysis revealed that low-CT density (compared with high-CT density) and sarcopenia and low-CT density (compared with non-sarcopenia and high-CT density as reference) increased mortality after TAVR (hazard ratios [HR]: 1.35 and 1.43, 95% confidence intervals [Cis]: 1.06–1.72 and 1.00–2.08, p = 0.01, and 0.049, respectively). However, sarcopenia alone was not related to an increased risk of mortality (HR 1.30, 95% CI 0.99–1.69, p = 0.52). In conclusion, CT density-based skeletal muscle quality assessment combined with the SMM index improves prediction of adverse outcomes after TAVR.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, PARTNER Trial Investigators (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198

  2. 2.

    Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, PARTNER 2 Investigators (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620

  3. 3.

    Yamamoto M, Shimura T, Kano S, Kagase A, Kodama A, Sago M, Tsunaki T, Koyama Y, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Watanabe Y, Hayashida K (2017) Prognostic value of hypoalbuminemia after transcatheter aortic valve implantation (from the Japanese Multicenter OCEAN-TAVI Registry). Am J Cardiol 119:770–777

  4. 4.

    Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, Tsuchikane E, Suzuki T, Otsuka T, Kohsaka S, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Watanabe Y, Hayashida K, on the behalf of OCEAN-TAVR Investigators (2017) Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation 135:2013–2024

  5. 5.

    Kano S, Yamamoto M, Shimura T, Kagase A, Tsuzuki M, Kodama A, Koyama Y, Kobayashi T, Shibata K, Tada N, Naganuma T, Araki M, Yamanaka F, Shirai S, Mizutani K, Tabata M, Ueno H, Takagi K, Higashimori A, Otsuka T, Watanabe Y, Hayashida K (2017) Gait speed can predict advanced clinical outcomes in patients who undergo transcatheter aortic valve replacement: insights from a Japanese Multicenter Registry. Circ Cardiovasc Interv 10(9):e005088. https://doi.org/10.1161/circinterventions.117.005088

  6. 6.

    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156

  7. 7.

    Boutin RD, Yao L, Canter RJ, Lenchik L (2015) Sarcopenia: current concepts and imaging implications. AJR AmJ Roentgenol 205(3):W255–W266

  8. 8.

    Mok M, Allende R, Leipsic J, Altisent OA, Del Trigo M, Campelo-Parada F, DeLarochellière R, Dumont E, Doyle D, Côté M, Freeman M, Webb J, Rodés-Cabau J (2016) Prognostic value of fat mass and skeletal muscle mass determined by computed tomography in patients who underwent transcatheter aortic valve implantation. Am J Cardiol 117:828–833

  9. 9.

    Garg L, Agrawal S, Pew T, Hanzel GS, Abbas AE, Gallagher MJ, Shannon FL, Hanson ID (2017) Psoas muscle area as a predictor of outcomes in transcatheter aortic valve implantation. Am J Cardiol 119:457–460

  10. 10.

    Kleczynski P, Tokarek T, Dziewierz A, Sorysz D, Bagienski M, Rzeszutko L, Dudek D (2018) Usefulness of psoas muscle area and volume and frailty scoring to predict outcomes after transcatheter aortic valve implantation. Am J Cardiol 122:135–140

  11. 11.

    Saji M, Lim DS, Ragosta M, LaPar DJ, Downs E, Ghanta RK, Kern JA, Dent JM, Ailawadi G (2016) Usefulness of psoas muscle area to predict mortality in patients undergoing transcatheter aortic valve replacement. Am J Cardiol 118(2):251–257

  12. 12.

    Mamane S, Mullie L, Piazza N, Martucci G, Morais J, Vigano A, Levental M, Nelson K, Lange R, Afilalo J (2016) Psoas muscle area and all-cause mortality after transcatheter aortic valve replacement: the Montreal-Munich Study. Can J Cardiol 32(2):177–182

  13. 13.

    van Vugt JLA, Gaspersz MP, Vugts J, Buettner S, Levolger S, de Bruin RWF, Polak WG, de Jonge J, Willemssen FEJA, Groot Koerkamp B, Ijzermans JNM (2019) Low skeletal muscle density is associated with early death in patients with perihilar cholangiocarcinoma regardless of subsequent treatment. Dig Surg 36(2):144–152

  14. 14.

    van Baar H, Beijer S, Bours MJL, Weijenberg MP, van Zutphen M, van Duijnhoven FJB, Slooter GD, Pruijt JFM, Dronkers JJ, Haringhuizen A, Spillenaar Bilgen EJ, Hansson BME, de Wilt JHW, Kampman E, Winkels RM (2018) Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncol 144(11):2139–2147

  15. 15.

    Yamashita M, Kamiya K, Matsunaga A, Kitamura T, Hamazaki N, Matsuzawa R, Nozaki K, Tanaka S, Nakamura T, Maekawa E, Masuda T, Ako J, Miyaji K (2017) Prognostic value of psoas muscle area and density in patients who undergo cardiovascular surgery. Can J Cardiol 33(12):1652–1659

  16. 16.

    Foldyna B, Troschel FM, Addison D, Fintelmann FJ, Elmariah S, Furman D, Eslami P, Ghoshhajra B, Lu MT, Murthy VL, Hoffmann U, Shah R (2018) Computed tomography-based fat and muscle characteristics are associated with mortality after transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr 12:223–228

  17. 17.

    Dahya V, Xiao J, Prado CM, Burroughs P, McGee D, Silva AC, Hurt JE, Mohamed SG, Noel T, Batchelor W (2016) Computed tomography–derived skeletal muscle index: a novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement. Am Heart J 182:21–27

  18. 18.

    Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33:2403–2418

  19. 19.

    Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89:104–110

  20. 20.

    Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E, Newman AB (2001) Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol (1985) 90(6):2157–2165

  21. 21.

    Chang CD, Wu JS, Mhuircheartaigh JN, Hochman MG, Rodriguez EK, Appleton PT, Mcmahon CJ (2018) Effect of sarcopenia on clinical and surgical outcome in elderly patients with proximal femur fractures. Skelet Radiol 47(6):771–777

  22. 22.

    DeAndrade J, Pedersen M, Garcia L, Nau P (2018) Sarcopenia is a risk factor for complications and an independent predictor of hospital length of stay in trauma patients. J Surg Res 221:161–166

  23. 23.

    Malietzis G, Currie AC, Athanasiou T, Johns N, Anyamene N, Glynne-Jones R, Kennedy RH, Fearon KC, Jenkins JT (2016) Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg 103(5):572–580

  24. 24.

    Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB (2006) Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci 61:72–77

  25. 25.

    Lenchik L, Lenoir KM, Tan J, Boutin RD, Callahan KE, Kritchevsky SB, Wells BJ (2019) Opportunistic measurement of skeletal muscle size and muscle attenuation on computed tomography predicts one-year mortality in medicare patients. J Gerontol A Biol Sci Med Sci 74(7):1063–1069

Download references

Acknowledgements

The authors thank the investigators and institutions that have participated in the OCEAN-TAVI registry.

Funding

The OCEAN-TAVI registry is supported by Edwards Lifesciences and Daiichi-Sankyo company.

Author information

Correspondence to Masanori Yamamoto.

Ethics declarations

Conflict of interest

Dr. Yamamoto, Dr. Tada, Dr. Naganuma, Dr. Shirai, Dr. Mizutani, and Dr. Watanabe are clinical proctors for Edwards Lifesciences and Medtronic. Dr. Araki, Dr. Tabata, Dr. Takagi, Dr. Higashimori, and Dr. Hayashida are clinical proctors of Edwards Lifesciences. Dr. Ueno is a clinical proctor for Medtronic. The remaining authors have nothing to disclose.

Informed consent

This study was approved by all institutional review boards that participated in the OCEAN-TAVI registry. The OCEAN-TAVI investigations was registered with the University Hospital Medical Information Network (no.: UMIN000020423). The medical ethics committees at all hospitals approved this study protocol, and written informed consent was obtained from all patients before TAVI.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tokuda, T., Yamamoto, M., Kagase, A. et al. Importance of combined assessment of skeletal muscle mass and density by computed tomography in predicting clinical outcomes after transcatheter aortic valve replacement. Int J Cardiovasc Imaging (2020). https://doi.org/10.1007/s10554-020-01776-x

Download citation

Keywords

  • OCEAN
  • Sarcopenia
  • Skeletal muscle density
  • Skeletal muscle mass
  • Transcatheter aortic valve replacement